603087 Gan & Lee Pharmaceuticals.
- 46.32
- -0.56-1.19%
Gan & Lee Pharmaceuticals. News
Research reports suggest that Orient Securities has given Gan & Lee Pharmaceuticals an initial 'buy' recommendation, marking a breakthrough in their overseas expansion and innovation.
Ganli Pharmaceutical (603087): Basic market volume and price have risen sharply, and innovation have ushered in breakthroughs
Research Nuggets丨Guotai Junan: Maintaining the “Gan Li Pharmaceutical Gains” Rating, R&D Pipeline Continues to Advance
Gan Li Pharmaceutical (603087) follow-up review: EU GMP inspections are being accelerated through R&D pipelines
Ganli Pharmaceutical (603087): Performance is in line with expectations, continues to collect and win bids, and future profits can be expected
Minsheng Securities released a research report on April 26 stating that it gave Ganli Pharmaceutical (603087.SH) a recommended rating. The main reasons for the rating include: 1) rapid growth in product sales, which turned a loss into a profit in 2023; 2)
Ganli Pharmaceutical (603087): High-speed batch procurement of core products won the bid for the entire line
Ganli Pharmaceutical (603087): Equity incentives show confidence, strong momentum for performance growth
Ganli Pharmaceutical (603087): The insulin leader has made a comeback, and domestic and foreign markets are blooming
Ganli Pharmaceutical (603087) Review for the third quarter of 2023: The company's performance continues to improve, and products can be expected to go overseas in the future
Ganli Pharmaceutical (603087) 2023 Third Quarter Report Review Report: Steady performance growth can be expected in overseas markets
Ganli Pharmaceutical (603087): Revenue side meets expectations, reduced cost rates drive profit growth
Ganli Pharmaceutical (603087): Returning to a path of high growth after three generations of leading domestic insulin collection
Gan Li Pharmaceutical (603087): Domestic pharmaceutical sales doubled, 2023H1 performance turned a loss into a profit
Ganli Pharmaceutical (603087) 2022 Interim Report Review: Collection Leads to Decline in Performance, Product Internationalization Continues
Ganli Pharmaceutical (603087) 2021 Report and 2022 Quarterly Report Reviews: Steady growth in performance and smooth progress in overseas business
Ganli Pharmaceutical (603087) 2021 Interim Report Review: H1 Performance Is Growing Rapidly, and the International Layout Continues to Advance
Ganli Pharmaceutical (603087): Investment in R&D led to a slowdown in profit growth, and the international layout is beginning to bear fruit
Ganli Pharmaceutical (603087): R&D investment continues to increase, and overseas layout is progressing smoothly
Ganli Pharmaceutical (603087): The time is right for a three-generation insulin leader to replace domestic production
Analysis
Price Target
No Data
